PMID: 9436780Jan 22, 1998Paper

Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B

Journal of Cardiovascular Electrophysiology
J SchreieckC Schmitt

Abstract

Blockade of the rapid delayed rectifier potassium current (IKr) as an important mechanism for current Class III antiarrhythmics is less effective in action potential prolongation during beta-adrenergic activation. We hypothesized that blockade of the increased slow IK (IKs) current during beta-adrenergic stimulation could improve action potential prolongation and tested this hypothesis by comparison of three different IK blockers: dofetilide, a selective blocker of IKr; ambasilide, a nonselective blocker of IK; and chromanol 293B, a selective blocker of IKs. Transmembrane action potential duration was determined in guinea pig papillary muscles. After equilibration with the potassium channel blockers (dofetilide 10 nM, ambasilide 10 microM, chromanol 293B 10 microM), isoproterenol (10 and 100 nM) was added. The action potential prolonging effect of dofetilide was reduced in the presence of increasing concentrations of isoproterenol whereas the effect of ambasilide was much less reduced. In contrast, the effect of chromanol 293B clearly was increased in the presence of both concentrations of isoproterenol. No afterdepolarizations were observed after application of isoproterenol in control. Following isoproterenol, but not before,...Continue Reading

References

Jul 1, 1977·Circulation·R H AndersonA E Becker
Oct 1, 1979·The American Journal of Cardiology·C P Reddy, L S Gettes
May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K Mackie, B Hille
Nov 1, 1990·Journal of the American College of Cardiology·A H KadishF Morady
Feb 1, 1986·The Journal of Physiology·E Carmeliet, K Mubagwa
Sep 1, 1989·Journal of the American College of Cardiology·M R JazayeriM Akhtar
Mar 1, 1985·Progress in Cardiovascular Diseases·S YusufP Sleight
Dec 1, 1987·Pflügers Archiv : European journal of physiology·H MatsuuraY Imoto
Oct 1, 1984·The American Journal of Cardiology·R A FreedmanJ W Mason
Oct 1, 1993·Canadian Journal of Physiology and Pharmacology·D NewmanR Feder-Elituv
Jun 1, 1993·Pflügers Archiv : European journal of physiology·P C LevesqueJ R Hume
Dec 15, 1995·Circulation·M W VeldkampL N Bouman
Feb 1, 1996·Naunyn-Schmiedeberg's Archives of Pharmacology·E Bassenge, B Fink
Oct 1, 1996·Pflügers Archiv : European journal of physiology·A E BuschJ G Maylie
Feb 1, 1996·Journal of Cardiovascular Electrophysiology·P T Sager, M Behboodikhah
Nov 15, 1996·Circulation·I I JoffeM N Kotler
Mar 1, 1997·Journal of the American College of Cardiology·J FiguerasJ Soler-Soler

❮ Previous
Next ❯

Citations

Jan 5, 2001·British Journal of Pharmacology·C LercheA E Busch
Dec 12, 2001·British Journal of Pharmacology·G SeebohmA E Busch
Feb 17, 1999·Pacing and Clinical Electrophysiology : PACE·N el-Sherif, G Turitto
Feb 28, 2003·Expert Opinion on Investigational Drugs·Jan Nemec, Win-Kuang Shen
May 15, 2009·Journal of Pharmacological and Toxicological Methods·Rob TowartDavid J Gallacher
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Paul DorianDavid Newman
Jan 20, 2004·American Journal of Physiology. Lung Cellular and Molecular Physiology·Christoph KarleHeimo Mairbäurl
Nov 22, 2000·Circulation·J P Mounsey, J P DiMarco
Feb 19, 2005·Circulation Research·Rodolphe P Katra, Kenneth R Laurita
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Bente BrendorpChristian Torp-Pedersen
Feb 9, 2007·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Norbert JostAndrás Varró
Sep 21, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bente BrendorpLars Køber
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Joseph J LynchDavid A Claremon
Jun 27, 2003·Journal of Cardiovascular Pharmacology·Gary L StumpJoseph J Lynch
Dec 22, 1999·Journal of Cardiovascular Pharmacology·X Q QiP Dorian
Dec 25, 2002·Journal of Cardiovascular Pharmacology·George P ThomasCharles Antzelevitch
Dec 24, 2002·Current Opinion in Cardiology·Nabil El-Sherif, Gioia Turitto
Nov 2, 2001·Journal of Medicinal Chemistry·U GerlachR Greger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.